Mind Medicine (MNMD) stock is rising by 15% since the beginning of the month and is still climbing, thus it grew by 2.8% yesterday and is expected to rise by another 1% today, standing at $3.62, representing one of the highest values throughout the last month.
MDIM, a leading clinical-stage pharmaceutical company and pioneer in the field of psychedelic-inspired drugs, today announced that J. R. Ran, the company’s co-founder, and CEO, is stepping down as CEO and Director and that Robert Barrow, the company’s Chief Development Officer, will take over as CEO immediately. The transition of the Company’s management team will allow the company to concentrate on aggressively implementing its clinical development programs and developing the new digital technologies that go along with them.
Psilocybin, LSD, MDMA, DMT, and the ibogaine derivative 18-MC are among the innovative psychedelic-based therapies that the company is developing. The Minded management team adds a wealth of biopharmaceutical experience to the company’s approach to developing psychedelic-inspired medications and treatments. MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ.